PSMA targeted nanobubbles for diagnostic and therapeutic applications
US10434194B2 · kind B2 · utility
4Cited by
6References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 30, 2017 |
| Grant date | Oct 8, 2019 |
| Priority date | — |
| Expiry date | Aug 30, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC08L2203/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A PSMA targeted nanobubble includes a membrane that defines at least one internal void, which includes at least one gas, and at least one PSMA ligand coupled or conjugated to the membrane. The membrane includes at least one lipid and at least one nonionic triblock copolymer that is effective to control the size of the nanobubble without compromising in vitro and in vivo echogenicity of the nanobubble.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.